JD
Therapeutic Areas
Genprex Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Reqorsa® (quaratusugene ozeplasmid) + Tagrisso® (osimertinib) | Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations post-Tagrisso failure | Phase 1/2 |
| Reqorsa® (quaratusugene ozeplasmid) + Tecentriq® (atezolizumab) | Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1/2 |
| Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab) | Non-Small Cell Lung Cancer (NSCLC) | Phase 1/2 |
| Reqorsa® + other TKIs | Various Cancers | Research |
| GPX-002 | Undisclosed Solid Tumor | Research |
Leadership Team at Genprex
RV
Rodney Varner
Chairman, President & Chief Executive Officer
RC
Ryan Confer
Chief Financial Officer
MB
Mark Berger
Chief Medical Officer
JL
Julien L. Pham
Chief Operating Officer
MT
Michael T. Redman
Executive Vice President, Corporate Development & Strategy
BL
Brent Longnecker
Director